Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027819 (neuroblastoma)
 27,800 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Members of children's cancer study group designed Study CCG 351 to determine whether three drug chemotherapy improved the survival experience of children with localized neuroblastoma. Patients in stages I-III were treated with surgical removal of the primary tumor and those in stages II and III received radiation therapy to the tumor bed and chemotherapy. Treatment included cyclophosphamide, imidazolecarboxamide, and vincristine given in 5-day pulses each month for 12 courses. The results were compared to those from a previous study, CCG 011, for localized neuroblastoma, in which children were randomized between a treatment regimen that included cyclophosphamide and one with no chemotherapy. There were 133 evaluable patients, subdivided as follows: stages I-26, stages II-74, and stages III-33. The 3-year life-table survival rates by stage of 96, 89 and 50% were not significantly different from the patients in CCG 011 similarly staged who received either no chemotherapy or oral CPM. These data suggest that multiagent chemotherapy, as prescribed, did not improve the outlook for children with locally advanced but nonmetastatic neuroblastoma. The staging criteria employed showed a modest difference in outcome between patients in stages I and II, but a significant poorer survival for stage III as compared to either stage I or II.
 ...
PMID:Results in children with local and regional neuroblastoma managed with and without vincristine, cyclophosphamide, and imidazolecarboxamide. A report from the Children's Cancer Study Group. 636 78

Clinical Stage IV-S neuroblastoma involving a primary, the liver, bone marrow, and/or skin has a favorable prognosis despite a considerable tumor burden. In a pilot experiment utilizing mouse C 1300 neuroblastoma, we demonstrated that animals receiving tumor to IV-S sites had a prolonged survival. To analyze the role which liver modulation of tumor might play in an immunologically mediated host-antitumor response, we applied an in vitro lymphocyte blastogenesis assay. Host-tumor response as reflected by blastogenesis and as quantified by tritiated thymidine incorporation into DNA demonstrated that normal lymphocytes were stimulated to a greater degree by subcutaneous site tumor than by tumor from the liver (260.7 +/- 71.9 vs. -54.2 +/- 194.3 CPM, p less than 0.05). Sensitized lymphocytes harvested from liver tumor bearers demonstrated a greater response when admixed with subcutaneous tumor in vitro (771.9 +/- 300.4 vs. 45.9 +/- 277.5 CPM, p less than 0.05) and sensitized lymphocytes harvested from subcutaneous tumor bearing animals also demonstrated more in vitro blastogenesis to subcutaneous tumor (577.9 +/- 200.2 vs. 98.9 +/- 154.1 CPM, p less than 0.05). However, host lymphocytes were themselves comparably reactive whether they were harvested from liver tumor or subcutaneous tumor donors (771.9 +/- 300.4 vs. 577.9 +/- 200.2, p = NS). These data suggest that lymphocytes in contact with murine liver neuroblastoma respond less well than when in contact with subcutaneous site tumor, a form of afferent blockade which may account for the propensity of the liver to serve as a site for metastatic disease.
 ...
PMID:Influence of primary tumor site on lymphocyte antitumor activity. 683 23

Neuroblastoma, common in children, rarely develops in adults. We recently treated a patient with adult neuroblastoma. A 34-year-old man complained of a swelling in right inguinal region. CT scan showed swelling of retroperitoneal and inguinal lymph nodes, and bone scintigram by 99mTc-HMDP showed an abnormal uptake in the swollen lymph nodes. Chemotherapy with CDDP (cisplatinum), VP-16 (etoposide), BLM (bleomycin), ADM (adriamycin) was not effective. Histopathological examination of a biopsy specimen revealed neuroblastoma. Another chemotherapy with CPM (cyclophosphamide), VCR (vincristine), ADM, DTIC (dacarbazine), CDDP, VP-16 was effective in decreasing the tumor size. Further high dose chemotherapy with CPM, ADM, CDDP, VP-16 combined with peripheral blood stem cell transplantation led to almost complete disappearance of the tumor and normalization of blood tumor markers (neuron specific enolase and immunosuppressive acidic protein). Retroperitoneal lymph node dissection demonstrated well-differentiated neuroblastoma in the excised tissue. Six months postoperatively, the tumor recurred in the pelvic cavity. Although chemotherapy and radiotherapy were given, he died of the disease 12 months postoperatively.
 ...
PMID:[A case of adult neuroblastoma arising in the retroperitoneal space]. 1159 7

Survival statistics from 50 children with disseminated neuroblastoma, treated according to two CCSGA protocols between 1966 and 1968, are compared to those collected by Sutow and associates for 1956 and 1962. Little improvement occurred in the median survival rates of the children in these groups. Survival at 24 months is 13, 22, and 13 per cent, respectively, for the three groups. The lack of improvement in the median survival rate following treatment with a combination of VCR and CPM is attributed to an initial response rate of less than 40 per cent in the treated patients. The survival of patients who did respond, when compared to those who did not, was twice as long (15 vs. 7 months). Clearly, improved chemotherapy or other modes of treatment are needed for patients with advanced neuroblastoma at the time of diagnosis.
 ...
PMID:The impact of chemotherapy on advanced neuroblastoma. Survival of patients diagnosed in 1956, 1962, and 1966-68 in Children's Cancer Study Group A. 1212 77